NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 23 04:00PM ET
1.63
Dollar change
+0.17
Percentage change
11.63
%
Index- P/E- EPS (ttm)-9.17 Insider Own1.72% Shs Outstand2.26M Perf Week15.60%
Market Cap3.68M Forward P/E- EPS next Y-0.85 Insider Trans0.00% Shs Float2.22M Perf Month-19.70%
Income-7.52M PEG- EPS next Q-0.89 Inst Own9.39% Short Float3.07% Perf Quarter-42.81%
Sales0.00M P/S- EPS this Y64.49% Inst Trans463.25% Short Ratio0.08 Perf Half Y-57.11%
Book/sh9.81 P/B0.17 EPS next Y73.93% ROA-42.80% Short Interest0.07M Perf Year-63.56%
Cash/sh6.84 P/C0.24 EPS next 5Y62.35% ROE-49.77% 52W Range1.21 - 23.80 Perf YTD-48.90%
Dividend Est.- P/FCF- EPS past 5Y45.91% ROI-46.04% 52W High-93.15% Beta0.43
Dividend TTM- Quick Ratio7.42 Sales past 5Y0.00% Gross Margin- 52W Low34.71% ATR (14)0.20
Dividend Ex-Date- Current Ratio7.42 EPS Y/Y TTM71.41% Oper. Margin- RSI (14)51.39 Volatility9.52% 12.81%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price12.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q59.80% Payout- Rel Volume0.07 Prev Close1.46
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMar 26 Avg Volume880.95K Price1.63
SMA2013.67% SMA50-14.28% SMA200-49.99% Trades Volume58,409 Change11.63%
Date Action Analyst Rating Change Price Target Change
May-22-20Downgrade B. Riley FBR Buy → Neutral $11 → $8
Feb-04-20Initiated Craig Hallum Buy $18
Jan-30-20Resumed Cantor Fitzgerald Overweight $9 → $14
Dec-02-19Initiated Canaccord Genuity Buy
Dec-12-18Initiated B. Riley FBR Buy $28
Aug-02-18Reiterated Maxim Group Buy $30 → $27
Jul-13-18Initiated Stifel Buy $35
Jul-12-18Initiated Cantor Fitzgerald Overweight $59
Jun-12-18Reiterated H.C. Wainwright Buy $24 → $43
Mar-15-18Upgrade Maxim Group Hold → Buy $14
Apr-17-25 08:30AM
Apr-15-25 08:30AM
Apr-10-25 08:00AM
Apr-02-25 04:10PM
Mar-20-25 08:55AM
08:29AM Loading…
Nov-15-24 08:29AM
Sep-25-24 08:00AM
Sep-20-24 09:00AM
Sep-19-24 07:00AM
Jun-22-24 09:52AM
Apr-10-24 06:30AM
Apr-05-24 09:53AM
Apr-04-24 05:06PM
Mar-15-24 09:00AM
Nov-21-23 07:32AM
04:32PM Loading…
Nov-20-23 04:32PM
Sep-26-23 08:30AM
Sep-22-23 04:05PM
Aug-10-23 11:08AM
Jul-14-23 09:20AM
Jul-10-23 08:00AM
Jun-01-23 08:05AM
08:00AM
May-09-23 07:00AM
May-04-23 04:00PM
Mar-29-23 05:00PM
Feb-08-23 08:00AM
Jan-06-23 06:34AM
Jan-04-23 08:00AM
Dec-14-22 05:00PM
12:00PM Loading…
Sep-14-22 12:00PM
Aug-04-22 08:00AM
Jul-18-22 11:43AM
Jul-13-22 10:53AM
Jul-07-22 10:18AM
07:30AM
Jun-17-22 04:15PM
Jun-15-22 10:47AM
May-17-22 08:00AM
07:30AM
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-26-22 08:30AM
Mar-29-22 10:18AM
Jan-11-22 07:30AM
Jan-10-22 07:30AM
Nov-08-21 07:30AM
07:00AM
Nov-01-21 12:38PM
10:10AM
Oct-11-21 08:00AM
Aug-24-21 12:03PM
Aug-19-21 11:49AM
08:00AM
Aug-16-21 08:00AM
Aug-11-21 12:48PM
Aug-10-21 03:41PM
Aug-05-21 07:00AM
Aug-03-21 04:49AM
Aug-02-21 09:26AM
07:30AM
Jul-29-21 08:30AM
Jun-04-21 06:57AM
May-13-21 07:50AM
06:30AM
May-06-21 08:30AM
May-03-21 08:30AM
Mar-19-21 07:23AM
Mar-18-21 07:00AM
06:30AM
Mar-16-21 08:00AM
Mar-11-21 08:30AM
Feb-16-21 09:29AM
06:48AM
Feb-11-21 11:16AM
Feb-04-21 01:30AM
Jan-26-21 08:00AM
Jan-19-21 08:00AM
Dec-17-20 07:00AM
Dec-04-20 09:08AM
Nov-12-20 07:00AM
06:45AM
Nov-10-20 08:40AM
Nov-09-20 08:00AM
Nov-05-20 08:30AM
Oct-20-20 08:31AM
Sep-10-20 08:49AM
Aug-06-20 07:00AM
06:50AM
Jul-30-20 08:30AM
Jul-22-20 10:34AM
Jul-14-20 05:31PM
Jul-06-20 07:55AM
Jun-26-20 06:42AM
Jun-10-20 08:34AM
May-14-20 05:31PM
07:00AM
May-07-20 08:30AM
May-02-20 09:36AM
Mar-26-20 09:40PM
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.